Portola Pharmaceuticals, Inc. (PTLA)

Oncology Corporate Profile

Stock Performance

24.6800
-0.4400

HQ Location

270 E. Grand Avenue
South San Francisco, CA 94080

Company Description

Portola Pharmaceuticals is focused on the development and commercialization of novel therapeutics to meet patient needs in thrombosis, other hematologic disorders and inflammation. Our current development-stage portfolio includes wholly-owned and partnered products. Portola's wholly-owned product candidate, cerdulatinib (PRT2070), is an orally available kinase inhibitor that uniquely inhibits two validated tumor proliferation pathways -- spleen tyrosine kinase (Syk) and janus kinase (JAK). It is currently being studied in patients with leukemias or lymphomas with a focus on genetically-defined subtypes, as well as in patients who have failed therapy due to relapse or acquired mutations.

Website: http://www.portola.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
cerdulatinib / PTR-2070dual tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.Chronic Lymphocytic Leukemia (CLL)II
cerdulatinib / PTR-2070dual tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.Non-Hodgkin's Lymphoma (NHL)I

View additional information on product candidates here »

Source: http://www.portola.com

Recent News Headlines

5/27/2017 06:19 am

5/27/2017 06:19 am

5/27/2017 06:19 am

5/27/2017 06:19 am

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/22/2017 06:18 am

5/22/2017 06:18 am

5/22/2017 06:18 am

5/22/2017 06:18 am

5/22/2017 06:18 am

5/18/2017 06:18 am

5/18/2017 06:18 am

5/18/2017 06:18 am

5/11/2017 12:18 pm

5/11/2017 12:18 pm

5/11/2017 12:18 pm

5/11/2017 12:18 pm

5/11/2017 06:19 am

5/11/2017 06:19 am

5/10/2017 06:19 am

5/10/2017 06:19 am

5/9/2017 12:19 pm

5/9/2017 06:19 am

5/9/2017 12:19 am